Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- B. Douglas Smith, MD
Sidney Kimmel Cancer Center at Johns Hopkins
Principal Investigator - David Snyder, M.D.
City of Hope Medical Center
Principal Investigator - H.Jean Khoury, MD
Emory University
Principal Investigator - Hedy P Smith, MD
Tufts Medical Center
Principal Investigator - Javier Pinilla-Ibarz, MD,PhD
H. Lee Moffitt Cancer Center and Research Institute
Principal Investigator - Kapil Bhalla, MD
University of Kansas
Principal Investigator - Moshe Talpaz, MD
Univ. of Michigan Comprehensive Cancer Center
Principal Investigator - Richard A Larson, MD
University of Chicago
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope
Duarte, California, United States
- H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
- Emory University
Atlanta, Georgia, United States
- University of Chicago
Chicago, Illinois, United States
- the University of Kansas Cancer Center
Kansas City, Kansas, United States
- Sidney Kimmel Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
- Tufts Medical Center
Boston, Massachusetts, United States
- University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2009
- Primary completion
- 31 Jan 2013
- Completion
- 31 Jan 2013
- Last update posted
- 18 Jul 2014
- Registered enrollment
- 57
- Registry id
- NCT00827138
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.